Zhimeng Biopharma Overview
- Founded
- 2015
- Status
- Private
- Latest Deal Type
- Early Stage VC
- Latest Deal Amount
- $14.2M
- Investors
- 3
Zhimeng Biopharma General Information
Description
Developer of pharmaceuticals designed to target all stages of the hepatitis B virus. The company has nuclecapsid inhibitor, RNA destabilizer and immunomodulator projects in the pipeline, enabling healthcare professionals to prescribe better treatments to patients.
Contact Information
Website
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Primary Office
- Room 5-N
- No. 780 Cailun Road, Pudong New Area
- Shanghai, 201203
- China
+86 021 0000 0000
Zhimeng Biopharma Timeline
Zhimeng Biopharma Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Early Stage VC | 11-Nov-2019 | $14.2M | 000.00 | Completed | Clinical Trials - Phase 1 | |
| 1. Early Stage VC | 05-Feb-2018 | Completed | Startup |
Zhimeng Biopharma Executive Team (2)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Huanming Chen Ph.D | Chief Executive Officer & Founder | ||
| Zhijun Zhang | Co- Founder, Chief Scientific Officer & Vice President |
Zhimeng Biopharma Investors (3)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| Shenzhen Capital Group | Venture Capital | Minority | 000 0000 | 000000 0 | |
| BOHE Angel Fund | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Legend Star | Corporate Venture Capital | Minority | 000 0000 | 000000 0 |